

Intravascular Lithotripsy for Calcified Peripheral Artery Disease (PAD) in Female vs Male Patients: Sex Specific Analysis from the Disrupt PAD III Observational Study



Characteristic	Women n = 377	Men n = 885	P-value
Age	73.6 ± 9.6	71.2 ± 8.6	<0.001
Hypertension	94.7%	93.6%	0.447
Hyperlipidemia	89.9%	88.8%	0.574
Diabetes mellitus	56.1%	55.9%	0.952
Coronary artery disease	57.3%	67.6%	<0.001
Prior myocardial infarction	19.0%	25.6%	<0.001
Prior CABG or stenting	45.7%	56.1%	<0.001
Renal insufficiency	27.2%	27.3%	0.958
On dialysis	21.6%	33.1%	0.033
Ankle-brachial index	0.7 ± 0.3	0.8 ± 0.3	0.003
Critical limb-threatening ischemia	38.4%	35.4%	0.303

Sameer Nagpal, Katharine McGinigle, Sarang Mangalmurti, George Adams, Anderson Mehrle, Peter A. Soukas, Barry Bertolet, Alexandra J. Lansky

Lesion Characteristic	Women n = 453	Men n = 1078	P-value
RVD, mm	5.3 ± 1.8	5.6 ± 1.6	0.009
MLD, mm	1.0 ± 1.1	1.2 ± 1.2	0.002
СТО	33.8%	30.0%	0.141
Lesion length, mm	88.8 ± 69.9	95.5 ± 76.1	0.098
Calcified length, mm	105.0 ± 80.4	118.6 ± 93.9	0.007
Moderate-severe calcification	86.5%	91.4%	0.005
Eccentric	18.1%	20.9%	0.217



Procedural Characteristics

Characteristic	Women n = 377	Men n = 885	P-value
Procedure time, min	91.6 ± 51.0	99.2 ± 54.2	0.020
Contrast volume, mL	144.1 ± 83.7	150.6 ± 86.0	0.218
Fluoroscopy time, min	23.4 ± 17.3	26.3 ± 20.2	0.010
Characteristic	Women n = 453 lesions	Men n = 1078 lesions	P-value
Embolic protection	5.1%	6.0%	0.071
Pre-dilatation	27.6%	30.2%	0.300
Post-IVL dilatation	77.5%	79.3%	0.424
IVL pulses	191.4 ± 98.8	190.1 ± 111.5	0.830
IVL as only Ca ⁺⁺ modifying therapy [*]	78.8%	77.5%	0 5 6 2
IVL + adjunctive Ca ⁺⁺ modifying therapy [*]	21.2%	22.5%	0.502



*Calcium-modifying therapy was used at operator's discretion and includes specialty balloons and/or atherectomy. DCB and/or stents used in both groups.

Conclusions

- Consistent procedural safety between women and men
- Consistent reduction in stenosis in both women and men
- IVL may be considered a front-line therapy for the treatment of heavily calcified PAD in both women and men

Disclosure

Funding for PAD III OS was provided by Shockwave Medical SPL-67405 Rev. A